| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Department of Neurology [S. W., B. S., M. M., D. S., M. W., H. W.] and Institute of Brain Research [R. M.], University of Tübingen, Medical School, D-72076 Tübingen, Germany, and Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905 [L. C.]
Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities. B7-homologue 1 (B7-H1), a recently identified homologue of B7.1/2 (CD80/86), has been described to exert costimulatory and immune regulatory functions. We investigated the expression and the functional activity of B7-H1 in human glioma cells in vitro and in vivo. Although lacking B7.1/2 (CD80/86), all 12 glioma cell lines constitutively expressed B7-H1 mRNA and protein. Exposure to IFN-
strongly enhanced B7-H1 expression. Immunohistochemical analysis of malignant glioma specimens revealed strong B7-H1 expression in all 10 samples examined, whereas no B7-H1 expression could be detected on normal brain tissues. To elucidate the functional significance of glioma cell-related B7-H1 expression, we performed coculture experiments of glioma cells with alloreactive CD4+ and CD8+ T cells. Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1). B7-H1 expression may thus significantly influence the outcome of T-cell tumor cell interactions and represents a novel mechanism by which glioma cells evade immune recognition and destruction.
This article has been cited by other articles:
|
|
 |
|
  M. Lafon, F. Megret, S. G. Meuth, O. Simon, M. L. Velandia Romero, M. Lafage, L. Chen, L. Alexopoulou, R. A. Flavell, C. Prehaud, et al. Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis J. Immunol., June 1, 2008; 180(11): 7506 - 7515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, and A. Nagler Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies Clin. Cancer Res., May 15, 2008; 14(10): 3044 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Jeong, Y.-J. Lee, S.-K. Seo, S.-W. Lee, S.-J. Park, J.-N. Lee, H.-S. Sohn, S. Yao, L. Chen, and I. Choi Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection J. Leukoc. Biol., March 1, 2008; 83(3): 755 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Roth, Y. Sheinin, C. M. Lohse, S. M. Kuntz, X. Frigola, B. A. Inman, A. E. Krambeck, M. E. Mckenney, R. J. Karnes, M. L. Blute, et al. B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy Cancer Res., August 15, 2007; 67(16): 7893 - 7900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Feger, E. Tolosa, Y.-H. Huang, A. Waschbisch, T. Biedermann, A. Melms, and H. Wiendl HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation Blood, July 15, 2007; 110(2): 568 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okazaki and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int. Immunol., July 2, 2007; (2007) dxm057v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood, July 1, 2007; 110(1): 296 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Waeckerle-Men, A. Starke, and R. P. Wuthrich PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1527 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher Jr., S. J. Yokota, and R. B. Bankert Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells J. Immunol., May 1, 2007; 178(9): 5552 - 5562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Krambeck, H. Dong, R. H. Thompson, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, M. L. Blute, T. J. Sebo, J. C. Cheville, A. S. Parker, et al. Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma Clin. Cancer Res., March 15, 2007; 13(6): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer PNAS, February 27, 2007; 104(9): 3360 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Thompson, H. Dong, and E. D. Kwon Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy Clin. Cancer Res., January 15, 2007; 13(2): 709s - 715s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Usui, Y. Okunuki, T. Hattori, M. Takeuchi, T. Kezuka, H. Goto, and M. Usui Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4607 - 4613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Krambeck, R. H. Thompson, H. Dong, C. M. Lohse, E. S. Park, S. M. Kuntz, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival PNAS, July 5, 2006; 103(27): 10391 - 10396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Thompson, S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, et al. Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Res., April 1, 2006; 66(7): 3381 - 3385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Roth, S. Aulwurm, I. Gekel, D. Beier, R. G. Sperry, M. Mittelbronn, R. Meyermann, K. D. Beaman, M. Weller, and J. Wischhusen Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. Cancer Res., April 1, 2006; 66(7): 3852 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Magnus, B. Schreiner, T. Korn, C. Jack, H. Guo, J. Antel, I. Ifergan, L. Chen, F. Bischof, A. Bar-Or, et al. Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS J. Neurosci., March 9, 2005; 25(10): 2537 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity Cancer Res., February 1, 2005; 65(3): 1089 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target PNAS, December 7, 2004; 101(49): 17174 - 17179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. He, G.-M. Zhang, X.-H. Wang, H. Zhang, Y. Yuan, D. Li, and Z.-H. Feng Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine J. Immunol., October 15, 2004; 173(8): 4919 - 4928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saudemont and B. Quesnel In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis Blood, October 1, 2004; 104(7): 2124 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression Clin. Cancer Res., August 1, 2004; 10(15): 5094 - 5100. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
